ALSACTIDE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C99H155N29O21S
Molecular Weight	2119.5417
Optical Activity	UNSPECIFIED
Defined Stereocenters	14 / 14
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)CCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCCCCN

InChI

InChIKey=DIDCGVRALANKIU-OTEFFYEFSA-N

InChI=1S/C99H155N29O21S/c1-59(2)84(97(148)113-56-81(132)115-68(26-10-14-40-101)87(138)119-69(27-11-15-41-102)88(139)118-67(25-9-13-39-100)85(136)109-45-18-17-43-104)127-96(147)79-30-20-47-128(79)98(149)73(28-12-16-42-103)116-82(133)55-112-86(137)76(51-62-53-111-66-24-8-7-23-65(62)66)124-89(140)70(29-19-46-110-99(106)107)120-93(144)75(49-60-21-5-4-6-22-60)123-94(145)77(52-63-54-108-58-114-63)125-90(141)71(35-36-83(134)135)121-91(142)72(38-48-150-3)122-95(146)78(57-129)126-92(143)74(117-80(131)37-44-105)50-61-31-33-64(130)34-32-61/h4-8,21-24,31-34,53-54,58-59,67-79,84,111,129-130H,9-20,25-30,35-52,55-57,100-105H2,1-3H3,(H,108,114)(H,109,136)(H,112,137)(H,113,148)(H,115,132)(H,116,133)(H,117,131)(H,118,139)(H,119,138)(H,120,144)(H,121,142)(H,122,146)(H,123,145)(H,124,140)(H,125,141)(H,126,143)(H,127,147)(H,134,135)(H4,106,107,110)/t67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,84-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C99H155N29O21S
Molecular Weight	2119.5417
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	14 / 14
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6091239 | https://www.ncbi.nlm.nih.gov/pubmed/3040344 | https://www.ncbi.nlm.nih.gov/pubmed/6091237

Alsactide (Synchrodyn) is synthesized heptadecapeptide analog of adrenocorticotropic hormone (ACTH) having a C-terminal amide group (butylamide) and the substitution of beta-alanine for serine in position 1 and of lysine for arginine in position 17. These modifications account for enhanced biological activity and uniquely demonstrated chronopharmacological properties. In adult healthy men, the tailoring of dosage and timing of peptide administration was successful in a selective and transient stimulation of glucocorticoid secretion, without a change in the plasma concentrations of aldosterone and testosterone. The clinical use of alsactide has provided new diagnostic information about subtle alterations of the adrenal function and has been valuable to presenting the rhythmic ordering of several functions, especially of those which are more dependent on the glucocorticoid modulation.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Adrenal insufficiency 3

Sample Use Guides

In Vivo Use Guide

10 ug

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:48:18 GMT 2025` Edited by `admin` on `Mon Mar 31 20:48:18 GMT 2025`
Record UNII	J0K70H3420
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

alsactide [INN]

Preferred Name

English

ALSACTIDE

Official Name

English

HOE-433

Code

English

ALSACTIDE [MI]

Common Name

English

.ALPHA.1-17-CORTICOTROPIN, 1-.BETA.-ALANINE-17-(N-(4-AMINOBUTYL)-L-LYSINAMIDE)-

Systematic Name

English

ALISACTIDE

Common Name

English

.ALPHA.1-17-CORTICOTROPIN, 1-.BETA.-ALANINE-17-(L-2,6-DIAMINO-N-(4-AMINOBUTYL)HEXANAMIDE)-

Systematic Name

English

1-.BETA.-ALANINE-17-(L-2,6-DIAMINO-N-(4-AMINOBUTYL)HEXANAMIDE)-.ALPHA.(SUP 1,17)-CORTICOTROPIN

Common Name

English

Alsactide [WHO-DD]

Common Name

English

SYNCHRODYN

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QV04CH04